Amlodipine

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Retrieved on: 
Sunday, April 7, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Blood pressure, Medication, Indapamide, Risk, Patient, Month, SBP, ABPM, American College, Olmesartan, Injection, Safety, RNA interference, Therapy, AGT, ACC, Amlodipine, Cardiomyopathy, Hypertension, Pharmaceutical industry

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.

Key Points: 
  • Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
  • The results were presented today as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
  • The Company previously announced positive topline results from the KARDIA-2 study in March 2024.
  • “Although many effective oral treatments are available, a large proportion of patients with hypertension are not managed to guideline-recommended targets.

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Blood pressure, DBP, Amlodipine, Roche, Month, Safety, Glomerular filtration rate, ABPM, Trial of the century, Cardiology, Indapamide, AGT, Hypertension, American College, SBP, EGFR, Patient, Angiotensin, DB, Alnylam Pharmaceuticals, Medication, RNA interference, Pharmaceutical industry

Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.

Key Points: 
  • Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.
  • “We are thrilled that a single dose of zilebesiran achieved clinically significant, additional reductions in systolic blood pressure when administered to patients who are not adequately controlled with commonly prescribed antihypertensives,” said Simon Fox, Ph.D., Vice President, Zilebesiran Program Lead at Alnylam.
  • “These KARDIA-2 results, showing durable additional levels of blood pressure reduction on top of what is achieved by standard of care first-line antihypertensives with an encouraging safety profile, reinforce our confidence in zilebesiran’s differentiated profile.
  • The primary endpoint is the change from baseline in mean SBP at Month 3, assessed by 24-hour ABPM.

epocrates Delivered Clinical and Commercial Innovation in 2023, Building a Foundation for Scale, Impact, and Engagement for its 1 million+ Physician User Base

Retrieved on: 
Tuesday, February 27, 2024
Apps, Applications, Technology, Nursing, Hospitals, Clinical Trials, Practice Management, Managed Care, Health, Pharmaceutical, CME, Behavior, Algorithm, BSN, Apixaban, Atorvastatin, Amlodipine, Intelligence, RN, Patient, University, Infection

The home screen and newsfeed are core experiences for epocrates users, and the company made several updates to bring educational and actionable information more front and center for clinicians.

Key Points: 
  • The home screen and newsfeed are core experiences for epocrates users, and the company made several updates to bring educational and actionable information more front and center for clinicians.
  • These updates include a new home page newsfeed on epocrates web, calls to action on newsfeed articles, and enhanced interactive functionality.
  • These enhancements serve to streamline clinicians’ experience while navigating the platform and offer information that may assist with patients they see in the future.
  • “The ability to purchase enterprise-wide subscriptions was something we'd been asking for and are pleased to see that it's now an option."

Discover this new generic drug in the PERINDOPRIL range

Retrieved on: 
Wednesday, February 21, 2024
Blood pressure, Essential hypertension, Amlodipine, Quality of life, Health, Patient, Tablet, Perindopril, Ageing, Pharmaceutical industry

This oral treatment contains two medicines, perindopril arginine and amlodipine.

Key Points: 
  • This oral treatment contains two medicines, perindopril arginine and amlodipine.
  • They work together to control the blood pressure.
  • pms-PERINDOPRIL-AMLODIPINE are available in bottles of 100 tablets and comes in the following dosage forms:
    This medication is a generic equivalent of Viacoram MD1.
  • « Perindopril Amlodipine is manufactured in our Canadian facility which is another example of how we leverage our expertise and capabilities to deliver value to our customers and patients.

Closed Loop Medicine Demonstrates Application of Novel Drug Plus Software Product for Personalized Treatment of Hypertension

Retrieved on: 
Thursday, February 8, 2024
Medical Devices, Health, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, COVID-19, Innovation, American College, Senior, Orthostatic hypertension, Medicine, Invention, Death, Amlodipine, Therapy, Disease, Drug intolerance, Patient, Cerebral edema, COVID, Triage, Trust, Hypertension, BP, Journal, American Heart Association, Journal of Human Hypertension, JAHA, Innovate UK, Blood pressure, Pharmaceutical industry

Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1).

Key Points: 
  • Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1).
  • Hypertension is the leading preventable cause of morbidity and premature death worldwide.
  • High adherence rates were reported (both app usage and medication) and patient retention was exceptionally high with no discontinuations due to drug intolerance.
  • Dr. Hakim Yadi OBE, CEO & Co-Founder of Closed Loop Medicine, commented: “These findings are invaluable in demonstrating the power of personalizing the dose of existing therapeutics in areas as widely impactful as hypertension.

Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Blood pressure, Medical Subject Headings, Heart failure, Marketing, Meal, Liver, INN, Risk, Cardiogenic shock, Woman, Heart rate, ATC, BPM, Blood, International, Moyamoya disease, Disease, NYHA, Language, Heart, Death, Angina, Coronary artery disease, Tablet, Select, Human, Patient, Facial muscles, Anatomy, Atenolol, IIA, Jaw, Exercise, Amlodipine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Blood pressure, Medical Subject Headings, Heart failure, Marketing, Meal, Liver, Agency, INN, Risk, Cardiogenic shock, Woman, Heart rate, ATC, BPM, Blood, International, Disease, NYHA, Language, Heart, Death, Angina, European Medicines Agency, Coronary artery disease, Tablet, Select, Human, Patient, Anatomy, Medicine, Atenolol, IIA, Jaw, Exercise, Amlodipine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Ivabradine Anpharm, ivabradine, Date of authorisation: 08/09/2015, Revision: 10, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Blood pressure, Medical Subject Headings, Heart failure, Marketing, Meal, Liver, Agency, INN, Risk, Cardiogenic shock, Woman, Heart rate, ATC, BPM, Blood, International, Disease, NYHA, Ivabradine, Language, Heart, Death, Angina, European Medicines Agency, Coronary artery disease, Tablet, Select, Human, Patient, Facial muscles, Anatomy, Atenolol, IIA, Jaw, Exercise, Amlodipine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Ivabradine Anpharm, ivabradine, Date of authorisation: 08/09/2015, Revision: 10, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ivabradine Anpharm, ivabradine, Date of authorisation: 08/09/2015, Revision: 10, Status: Authorised

Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board

Retrieved on: 
Monday, July 31, 2023
Clinical Science (journal), Disulfiram-like drug, GSK plc, Insulin resistance, OAU, Pregnancy, University, PD, Internal medicine, Pharmacovigilance, Roche, Big Pharma, COVID-19, Baylor University, Clinical trial, Pharmacokinetics, ACEI, Viral, Medicine, CMO, Doctor of Philosophy, Perindopril, Literature, Galectin-3, MD, Cilazapril, Saint James School of Medicine, Amlodipine, Merck, Type, Ross University, Pharmacology, Safety, Obafemi Awolowo University, Academic and Research Center (Ohio University), Conditional sentence, Pharmaceutical industry, Outline of health sciences, Pfizer

He will report to the CEO Dr David Platt and chair the Medical Advisory Board.

Key Points: 
  • He will report to the CEO Dr David Platt and chair the Medical Advisory Board.
  • He is a fully trained physician leader with international specialty training in internal medicine, cardiovascular medicine, and clinical pharmacology.
  • Bioxytran has one of the most ambitious pipeline buildouts I have every seen,” said Dr. Leslie Ajayi.
  • I also look forward to building out the medical advisory board.”

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2

Retrieved on: 
Wednesday, July 12, 2023
Telmisartan, Diabetes, Disability, ICTU, Indapamide, Hypertension, Patient, Amlodipine, Death, Imperial College London, Safety, Pharmaceutical industry, Novel

George Medicines’ mission is to extend and improve the lives of the millions of people suffering from non-communicable cardiometabolic diseases – the world’s leading causes of death and disability, including hypertension and diabetes.

Key Points: 
  • George Medicines’ mission is to extend and improve the lives of the millions of people suffering from non-communicable cardiometabolic diseases – the world’s leading causes of death and disability, including hypertension and diabetes.
  • Globally, over a billion people worldwide have hypertension but fewer than one in five have the condition under control.
  • GMRx2 is formulated in novel, patent-protected low and ultra-low doses, to be a simple, go-to solution to reach targeted blood pressure control across different patient types.
  • Dr. Karl Roberts, Chief Operating Officer of George Medicines, said: “The progress of this Phase III programme is a huge testament to the dedication of the team and our partners working to bring GMRx2 to patients.